<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24809726</article-id><article-id pub-id-type="pmc">4014606</article-id><article-id pub-id-type="publisher-id">PONE-D-14-05703</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0097150</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Clinical Immunology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject></subj-group><subj-group><subject>Infectious Diseases</subject></subj-group><subj-group><subject>Oncology</subject></subj-group><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Global Health</subject></subj-group></subj-group><subj-group><subject>Women's Health</subject><subj-group><subject>Obstetrics and Gynecology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Research and Analysis Methods</subject><subj-group><subject>Research Design</subject><subj-group><subject>Clinical Research Design</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>The Association between HIV Infection, Antiretroviral Therapy and Cervical Squamous Intraepithelial Lesions in South Western Nigerian Women</article-title><alt-title alt-title-type="running-head">Antiretroviral Therapy Reduced Cervical Precancerous Lesion Risk</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ezechi</surname><given-names>Oliver Chukwujekwu</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pettersson</surname><given-names>Karen Odberg</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Okolo</surname><given-names>Clement Abu</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ujah</surname><given-names>Innocent Achaya O.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ostergren</surname><given-names>Per Olof</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Clinical Sciences Division, Nigerian Institute of Medical Research Yaba, Lagos, Nigeria</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Social Medicine and Global Health, Faculty of Medicine, Lund University, Lund Sweden</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department of Pathology, College of Medicine, University of Ibadan, Ibadan, Nigeria</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Men&#x000e9;ndez-Arias</surname><given-names>Luis</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Centro de Biolog&#x000ed;a Molecular Severo Ochoa (CSIC-UAM), Spain</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>oezechi@yahoo.co.uk</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: OCE KOP CAO IAOU POO. Performed the experiments: OCE KOP CAO IAOU POO. Analyzed the data: OCE KOP IAOU POO. Contributed reagents/materials/analysis tools: OCE KOP CAO IAOU POO. Wrote the paper: OCE KOP CAO IAOU POO.</p></fn></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>8</day><month>5</month><year>2014</year></pub-date><volume>9</volume><issue>5</issue><elocation-id>e97150</elocation-id><history><date date-type="received"><day>6</day><month>2</month><year>2014</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 Ezechi et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Ezechi et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Findings from studies that evaluated the effect of antiretroviral drug use on the development of cervical squamous intraepithelial lesion differed in their conclusions. This study investigated the association between HIV infection, antiretroviral drug use and cervical squamous intraepithelial lesion in a high HIV and cervical cancer burden setting- Nigeria.</p></sec><sec><title>Methods</title><p>A cross sectional study among 1140 women of known HIV status enrolled in a randomised study to determine the test characteristics of visual inspection in detecting cytology diagnosed squamous intraepithelial lesion. Multivariate analysis was used to determine the association between HIV infection, antiretroviral drug use and the twin outcome variables of cervical squamous intraepithelial lesion (SIL) and High grade squamous intraepithelial lesion (HSIL) while controlling for confounders.</p></sec><sec><title>Results</title><p>Prevalence of cervical squamous intraepithelial lesion was 8.5%, with a higher prevalence of 14.3% in HIV positive compared to 3.3% in HIV negative women (aOR: 5.4; 95% CI: 2.9&#x02013;8.8). Not using antiretroviral drugs was found to be associated with an increased risk of SIL (aOR: 2.1; 95% CI: 1.4&#x02013;3.5) and HSIL (aOR: 2.6; 95% CI: 1.1&#x02013;6.4). Participants who had a CD4 cell count &#x0003c;200 cells/mm<sup>3</sup>, were also found to be at increased risk for SIL (aOR: 1.9; 95% CI: 1.1&#x02013;5.9) and HSIL (aOR: 5.7; 95% CI: 1.1&#x02013;7.2).</p></sec><sec><title>Conclusion</title><p>HIV infection and severe immunosuppression were found to be associated with increased risk of cervical squamous intraepithelial lesion but not viral load. For the first time, in the West African sub-region with specific HIV type and strains, we established the protective effect of antiretroviral drug use against the development of SIL. Integration of cervical cancer screening programme into HIV services and early initiation of antiretroviral drug in HIV positive women especially those with severe immune-suppression could therefore prove to be useful in preventing and controlling cervical cancer development in HIV positive women.</p></sec></abstract><funding-group><funding-statement>Funding from OE&#x02019;s research budget at Nigerian Instiute of Medical Research (NIMR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The introduction of, and improved access to highly active antiretroviral therapy (HAART) has had a dramatic impact on morbidity and mortality among individuals living with human immunodeficiency virus <xref rid="pone.0097150-Musa1" ref-type="bibr">[1]</xref>, <xref rid="pone.0097150-Shah1" ref-type="bibr">[2]</xref>, <xref rid="pone.0097150-Jevtovi1" ref-type="bibr">[3]</xref>. However, information on the impact of HAART on the natural history and treatment outcomes of HIV-associated malignancies are limited<xref rid="pone.0097150-Bernstein1" ref-type="bibr">[4]</xref>. The possibility of direct and indirect roles of HIV in HIV-related carcinogenesis suggests that antiretroviral therapy may be an important component of the treatment strategy for some AIDS defining malignancies <xref rid="pone.0097150-Bernstein1" ref-type="bibr">[4]</xref>, <xref rid="pone.0097150-Adler1" ref-type="bibr">[5]</xref>, <xref rid="pone.0097150-Gates1" ref-type="bibr">[6]</xref>.</p><p>Despite availability of studies that examined the effects of antiretroviral drug use on the course of cervical lesions in HIV positive women, the impact of the use of antiretroviral drug on the course of cervical lesions remains somewhat unclear <xref rid="pone.0097150-Odida1" ref-type="bibr">[7]</xref>&#x02013;<xref rid="pone.0097150-Zeier1" ref-type="bibr">[13]</xref>. While some studies <xref rid="pone.0097150-Sekirime1" ref-type="bibr">[10]</xref>&#x02013;<xref rid="pone.0097150-Firnhaber1" ref-type="bibr">[12]</xref>, <xref rid="pone.0097150-Blitz1" ref-type="bibr">[15]</xref>, <xref rid="pone.0097150-Chen1" ref-type="bibr">[16]</xref>. reported an association between antiretroviral drugs use and a lower incidence of cervical lesions, others have reported no beneficial effect of antiretroviral drug use on the incidence of cervical lesions <xref rid="pone.0097150-Odida1" ref-type="bibr">[7]</xref>&#x02013;<xref rid="pone.0097150-Firnhaber1" ref-type="bibr">[12]</xref>, <xref rid="pone.0097150-McKenzie1" ref-type="bibr">[17]</xref>, <xref rid="pone.0097150-Mogtomo1" ref-type="bibr">[18]</xref>. The inconsistency of findings in the cited studies might be the effect of small sample size, differing analytic techniques, viral diversity as well as timing and duration of treatment with antiretroviral drugs <xref rid="pone.0097150-Xi1" ref-type="bibr">[14]</xref>, <xref rid="pone.0097150-McKenzie1" ref-type="bibr">[17]</xref>.</p><p>It is now more than 10 years since the Government of Nigeria introduced an antiretroviral drugs access programme. Over half a million adults have initiated treatment, 60% of whom are women<xref rid="pone.0097150-Musa1" ref-type="bibr">[1]</xref>. Unfortunately, little or no information exists on the impact of antiretroviral drug use on cervical lesions among women benefitting from the programme. The focus of published studies has been on prevalence and burden of cervical precancerous and invasive lesions among HIV-infected Nigerian women <xref rid="pone.0097150-Agaba1" ref-type="bibr">[19]</xref>&#x02013;<xref rid="pone.0097150-Swende1" ref-type="bibr">[22]</xref>. Detailed literature search identified no study in our sub region that has evaluated the effect of HIV infection, immunosuppression and antiretroviral drug use on the burden and distribution of cervical squamous intraepithelial lesions.</p><p>In this study, we investigated the association between HIV infection, immunosuppression, antiretroviral drug use and cervical squamous intraepithelial lesions in a setting endemic for both HIV and cervical cancer.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Ethical Considerations</title><p>Approval for the study was obtained from the Institutional Review Board, Nigerian Institute of Medical Research (NIMR), Lagos Nigeria. A written informed consent was obtained from the women invited to be part of the study after detailed information about the study. Impartial witnesses who were not members of study staff assisted the consenting process for low literates.</p></sec><sec id="s2b"><title>Study Design and Setting</title><p>A cross-sectional study among 1140 women of known HIV status enrolled in a study to evaluate the test characteristics of direct visual inspection in detecting cytology diagnosed cervical squamous intraepithelial lesion in Nigerian women of known HIV status.</p><p>Participants were recruited at the cervical cancer screening clinic, NIMR, Lagos, and from10 communities of Lagos and Ogun States of Nigeria during community cervical cancer screening outreach programmes. Women who presented for cervical cancer screening at the clinic and during the community outreach programmes were screened for eligibility for recruitment into the main study.</p><p>NIMR, the apex medical research institution in Nigeria, hosts a HIV treatment Centre that currently provides comprehensive HIV services for over 20,000 patients of whom 62.9% are women. Approximately 80% of the Centre&#x02019;s patients come from Lagos and Ogun state and all services are provided free of charge.</p></sec><sec id="s2c"><title>Study Population</title><p>The study population consists of adult females aged 18 years and above, seen either at the cervical cancer screening clinic, NIMR, Lagos or during the community cervical cancer screening outreach programmes.</p></sec><sec id="s2d"><title>Cytology Sample Collection and Analysis</title><p>Midwives and physicians trained specifically for this study performed all clinical examinations and the sample collection for Cervical Pap tests. Cervical samples collected on Ayres spatula and smeared on the slides were immediately fixed with commercial fixator before transportation to Department of Anatomic Pathology, University College Hospital Ibadan, Nigeria for interpretation according to Bethesda system. The cytopathologists who performed the cytological analyses were blinded to the participant&#x02019;s HIV status. A senior pathologist read all tests originally classified as abnormal and 15% of those classified as normal. All slides were pre-coded with the participants&#x02019; study number before samples were taken. In the event of disagreement between the cytopathologist&#x02019;s and the senior pathologist&#x02019;s report, the slides were sent to another senior pathologist for an independent review. For all such cases, that review constituted the final diagnosis.</p></sec><sec id="s2e"><title>Laboratory Tests</title><p>HIV test was conducted according to Nigerian National HIV testing and counselling guidelines in all women before enrolment into the study. Diagnosis was based on positive test on double ELISA based algorithm.</p><p>Viral load and CD4 cell count tests were conducted at the Human Virology Laboratory, NIMR, Lagos. Whole blood of the HIV positive women was used to perform CD4 assay, using the Cyflow Counter and Kits (Partec, Germany) according to the manufacturer&#x02019;s instructions. The viral load assay was performed using Roche Amplicor HIV-1 monitor test (version 1.5) according to manufacturer&#x02019;s instruction.</p></sec><sec id="s2f"><title>Data Collection and Analysis</title><p>Information on the socio-demographic, sexual and reproductive characteristics, HIV treatment history was collected by trained midwives and physicians using a study record form. The laboratory information (HIV status, CD4 cell count, HIV plasma viral load and cytology) were extracted from the participant&#x02019;s laboratory results and entered into the relevant portion of the study record form by trained staff. The entered information was cross-checked with the laboratory results to avoid entry error.</p><p>Information entered into the study record forms were doubly entered into study database by two trained data clerks. Information from the two databases was compared and any observed disparities were corrected using the individual case record forms. Coded information were then analysed using the SPSS version 19.0 (SPSS Inc. Chicago, IL) statistical package. The main outcome variables were cervical squamous intraepithelial lesions (SIL) and High grade squamous intraepithelial lesions (HSIL). For the analysis and as per Bethesda classification, atypical squamous cell of undetermined significance was distinguished from either squamous intraepithelial lesion or high grade squamous intraepithelial lesion and treated as a distinct category. First level analysis was conducted to determine the overall prevalence of cervical cell abnormality, SIL and HSIL, among the women and the prevalence of SIL and HSIL by HIV status. Second level analysis was then performed to assess the association between socio-demographic factors, sexual and reproductive characteristics, HIV treatment history and the two outcome variables. All factors independently associated with SIL and HSIL at the second level analysis were considered confounding variables and introduced in a step-wise manner in three different models of multivariate regression. In the first step, we started with the crude association between the cofounding variables and outcome variables adjusted by age and marital status (Model 1). Secondly, we adjusted for HIV status and treatment (Model 2) and finally we adjusted for other variables that were shown to be significantly associated with SIL and HSIL (Model 3). The results are presented as Odds ratios (OR) or adjusted ORs and their 95% confidence intervals (CI).</p></sec><sec id="s2g"><title>Determination of Sample Size</title><p>The prevalence of abnormal cervical cytology of 57.5% among women reported by Agaba et al in Jos, Nigeria was used as a reference value for the calculation of sample size <xref rid="pone.0097150-Agaba1" ref-type="bibr">[19]</xref>. Though this prevalence is considerably higher than a range of 5.0&#x02013;6.8% <xref rid="pone.0097150-Anorlu1" ref-type="bibr">[23]</xref>&#x02013;<xref rid="pone.0097150-Pimentel1" ref-type="bibr">[25]</xref> reported among HIV negative women in Nigeria, the higher prevalence was used because of the large proportion of HIV positives in this study. The minimum sample size for a statistically meaningful deduction was determined using the formula: N&#x0200a;=&#x0200a;Z&#x003b1;<sup>2</sup>P (1-P)/d2, where Z&#x003b1; is the Z statistic for a 95% confidence level, N is the sample size, p is the prevalence of cervical cell abnormality, and d is the precision. Based on this calculation, screening 720 women aged 18 years and above was considered sufficient for identifying a reliable estimate of the prevalence of women with cervical cell abnormality (CCA).</p></sec><sec id="s2h"><title>Definition of Variables</title><list list-type="bullet"><list-item><p>HIV treatment status: The use of antiretroviral therapy among HIV positive women for at least 3 months.</p></list-item><list-item><p>Viral load: The level of HIV-1 RNA copies/mL of plasma measured by Roche Ampliclor HIV-1 monitor test (version 1.5). HIV viral load value during analyses was dichotomized into two using 1000 copies regarded as the threshold for low viraemia.</p></list-item><list-item><p>CD4 Cell count: The level of the body&#x02019;s immunity measured as the number of CD4 T lymphocytes per mm<sup>3</sup> of blood by Cyflow Counter and Kits. CD4 cell count during analyses was dichotomized into two using 200 cell/mm<sup>3</sup> as cut off point. The immune system is adjudged as severely compromised at levels below 200.</p></list-item><list-item><p>Cervical cell abnormality (CCA): Any of atypical squamous cell, low grade squamous intraepithelial lesion, high grade squamous intraepithelial lesion or invasive cancer found in the cytology.</p></list-item><list-item><p>Atypical squamous cell abnormality of undetermined significance (ASC-US)<xref rid="pone.0097150-Davey1" ref-type="bibr">[26]</xref>: Cellular abnormalities that are more marked than those attributable to reactive changes but that quantitatively or qualitatively fall short of a definitive diagnosis of low-grade squamous intraepithelial lesion. Not included as squamous intraepithelial lesion and distinguished from Atypical Squamous Cell cannot exclude high grade squamous intraepithelial lesion (ASC-HSIL).</p></list-item><list-item><p>Low grade Squamous Intraepithelial Lesion (LSIL))<xref rid="pone.0097150-Davey1" ref-type="bibr">[26]</xref>: Encompassing: HPV/mild dysplasia/cervical intraepithelial neoplasia (CIN) 1.</p></list-item><list-item><p>High grade Squamous Intraepithelial Lesion (HSIL))<xref rid="pone.0097150-Davey1" ref-type="bibr">[26]</xref>: Encompassing: moderate and severe dysplasia, carcinoma in situ (CIS)/CIN 2 and CIN 3, with features suspicious for invasion.</p></list-item><list-item><p>Squamous Intraepithelial Lesion (SIL) )<xref rid="pone.0097150-Davey1" ref-type="bibr">[26]</xref>: Encompasses all cases of LSIL and HSIL.</p></list-item><list-item><p>Age at first intercourse: The age of the participants at her first penetrative vaginal intercourse.</p></list-item><list-item><p>Life time sexual partners: The total number of participants&#x02019; sexual partner at the time of recruitment.</p></list-item><list-item><p>Duration of ARV drug use: The time elapsed since commencement of antiretroviral therapy.</p></list-item></list></sec></sec><sec id="s3"><title>Results</title><p>A total of 1156 women were enrolled into the study. The 1140 (98.6%; 531 HIV positives and 609 HIV negatives) women with cytology reports were included in the analysis. Cytology results for the remaining 23 women were excluded due to failure of collecting smear because of vaginal atresia/uncooperative participant (5) and participant&#x02019;s refusal to allow pelvic examination and specimen collection after consenting process (8).</p><sec id="s3a"><title>Cytology Quality Control</title><p>A total of 358 (31.4%) slides were reviewed as per protocol. There were discordant results in only seventeen (4.7%) of cases originally diagnosed as ASC-US. Independent review concurred in ten (58.8%), downgraded as normal in six (35.3%) and upgraded one in (5.9%) to low grade squamous intraepithelial lesions. The original review accuracy was thus 98.5%.</p></sec><sec id="s3b"><title>Participants&#x02019; Characteristics</title><p>The demographic and biologic characteristics of the 1140 participants with cytology reports are shown in <xref ref-type="table" rid="pone-0097150-t001">table 1</xref>. About two-third of the women were older than 35 years of age (60.9%) with a median age of 37 years [IQR: 31&#x02013;45]. A majority of the women were married (66.9%), residing in urban community (57.6%) and had completed at least a secondary education (77.0%). Most women were employed (85.1%) and had at least one child (81.5%). Sexual debut occurred between the ages 15 and 24 years for most women (81.2%, mean: 20.4&#x000b1;3.9). Over 70% of the women reported total lifetime sexual partners of at least 2 (77.1%, mean: 3.0&#x000b1;2.5). Among the HIV positive participants, the majority had CD4 cell count above 200 cells/mm<sup>3</sup> (91.9%, mean: 532&#x000b1;268,4) and viral load less than 1000 copies per ml (73.1%, mean: 94676.8&#x000b1;692581.9). Most of the HIV positive women in the study were on antiretroviral drugs (76.1%). Of the 404 HIV positive women on antiretroviral drugs, 231(57.2%) have been on treatment for more than 3 years. Further analysis on the relationship between age at sexual debut and number of life time sexual partners showed that 52.4% (332) of the 633 women that had sexual debut after 20 years reported having had at least four sexual partners compared to only 28.4% (114/401) of 401 that had sexual debut before 20 years (p&#x0200a;=&#x0200a;0.00; OR: 2.8; 95% CI: 2.1&#x02013;3.7).</p><table-wrap id="pone-0097150-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0097150.t001</object-id><label>Table 1</label><caption><title>Socio-demographic and biologic characteristics of the 1133 women in the study.</title></caption><alternatives><graphic id="pone-0097150-t001-1" xlink:href="pone.0097150.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Characteristics</td><td align="left" rowspan="1" colspan="1">Number of women [n&#x0200a;=&#x0200a;1140(%)]</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Age (years; 1135)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">18&#x02013;24</td><td align="left" rowspan="1" colspan="1">48 (4.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">25&#x02013;34</td><td align="left" rowspan="1" colspan="1">395 (34.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">35&#x02013;44</td><td align="left" rowspan="1" colspan="1">358 (31.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;45</td><td align="left" rowspan="1" colspan="1">334(29.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Educational Status (1140)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">89(7.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Primary</td><td align="left" rowspan="1" colspan="1">173 (15.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Secondary</td><td align="left" rowspan="1" colspan="1">446(39.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Tertiary</td><td align="left" rowspan="1" colspan="1">432(37.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Marital status (1134)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Never married</td><td align="left" rowspan="1" colspan="1">192 (16.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Married</td><td align="left" rowspan="1" colspan="1">759 (66.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Divorced/Separated</td><td align="left" rowspan="1" colspan="1">60(5.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Widow</td><td align="left" rowspan="1" colspan="1">123(10.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Ethnic Group (1126</bold>)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yoruba</td><td align="left" rowspan="1" colspan="1">378(33.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Igbo</td><td align="left" rowspan="1" colspan="1">301(26.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hausa/Fulani</td><td align="left" rowspan="1" colspan="1">96(8.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Northern Minority</td><td align="left" rowspan="1" colspan="1">113(10.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Southern Minority</td><td align="left" rowspan="1" colspan="1">226(20.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">others</td><td align="left" rowspan="1" colspan="1">9(0.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Residence(1140)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Urban</td><td align="left" rowspan="1" colspan="1">657 (57.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Rural</td><td align="left" rowspan="1" colspan="1">483 (42.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Occupation(1136)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Unemployed</td><td align="left" rowspan="1" colspan="1">163 (14.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unskilled</td><td align="left" rowspan="1" colspan="1">380(33.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Skilled</td><td align="left" rowspan="1" colspan="1">449(39.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Professionals/Business Executive</td><td align="left" rowspan="1" colspan="1">144(12.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age at first intercourse (years;1034)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;15</td><td align="left" rowspan="1" colspan="1">26(2.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">15&#x02013;19</td><td align="left" rowspan="1" colspan="1">375(36.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">20&#x02013;24</td><td align="left" rowspan="1" colspan="1">465(44.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;25</td><td align="left" rowspan="1" colspan="1">168 (16.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Life time sexual partners (1063)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">313 (22.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">2&#x02013;4</td><td align="left" rowspan="1" colspan="1">571 (53.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">5&#x02013;9</td><td align="left" rowspan="1" colspan="1">139(13.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;10</td><td align="left" rowspan="1" colspan="1">40(3.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Parity (1108)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">205 (18.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">1&#x02013;4</td><td align="left" rowspan="1" colspan="1">731 (66.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;5</td><td align="left" rowspan="1" colspan="1">172 (15.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>HIV status (1140)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">609(53.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">531(46.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>CD4 cell count (Cells/mm<sup>3</sup>)</bold>
<xref ref-type="table-fn" rid="nt101">*</xref>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;200</td><td align="left" rowspan="1" colspan="1">43 (8.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">200&#x02013;499</td><td align="left" rowspan="1" colspan="1">224 (42.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;500</td><td align="left" rowspan="1" colspan="1">264 (49.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>HIV viral load (Copies/ml)</bold>
<xref ref-type="table-fn" rid="nt101">*</xref>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;1000</td><td align="left" rowspan="1" colspan="1">387 (73.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">1000&#x02013;9999</td><td align="left" rowspan="1" colspan="1">35 (6.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;10,000</td><td align="left" rowspan="1" colspan="1">109 (20.5</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Antiretroviral drug use</bold>
<xref ref-type="table-fn" rid="nt101">*</xref>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Not on drugs</td><td align="left" rowspan="1" colspan="1">127 (23.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">On drugs</td><td align="left" rowspan="1" colspan="1">404 (76.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Duration of ARV drug use</bold>
<xref ref-type="table-fn" rid="nt101">*</xref>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;3 years</td><td align="left" rowspan="1" colspan="1">228(42.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">3&#x02013;5 years</td><td align="left" rowspan="1" colspan="1">161(30.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Above 5 years</td><td align="left" rowspan="1" colspan="1">142(26.7)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>
<bold>*HIV positive women only.</bold>
</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>Prevalence and Distribution of Cervical Squamous Intraepithelial Lesions</title><p>Two hundred and twenty (19.3%) women out of the 1140 women in the study had a cytology report of CCA. Of the 220 women with CCA cytology report, 121 (55.0%) were reported as atypical squamous cell abnormality of undetermined significance (ASC-US. Ninety-six (44.0%) were reported as squamous intraepithelial lesion (SIL) and two (0.9%) as invasive cancer and atypical glandular cell abnormality in one (0.5%) woman. Of the 96 women with SIL cytology report, 67 (69.8%) were further classified as low grade squamous intraepithelial lesion and 29 (30.2%) as high grade squamous intraepithelial lesion (HSIL). The prevalence of SIL and HSIL among the 1140 women in the study was thus 8.4% (67/1140) and 2.5% (29/1140) respectively. While 76 (14.3%) and 23 (4.3%) of the 531 HIV positive women were reported to have an abnormal cytology finding of SIL and HSIL respectively, 20 (3.3%) and six (1.0%) of the 609 HIV negative women were found to have SIL and HSIL respectively. The three women with invasive cancer (2) and atypical glandular cell abnormality (1) were all HIV-positive.</p></sec><sec id="s3d"><title>Distribution of Sociodemographic and Biological Characteristics by Cervical Smear Status</title><p>
<xref ref-type="table" rid="pone-0097150-t002">Table 2</xref> shows the prevalence of SIL and HSIL by exposure variable. Participants who reported more than one life time sexual partner (OR: 2.9; 95% CI: 1.6&#x02013;5.4), were unmarried (OR: 1.6; 95% CI: 1.0&#x02013;2.6) and initiated sex after age of 20 years (OR: 17.7; 95% CI: 6.2&#x02013;57.0) were more likely to have cervical smear report of SIL. HIV positive status (OR: 5.8; 95% CI: 3.3&#x02013;10.0), non-use of antiretroviral drugs by HIV positives (OR: 2.0; 95% CI: 1.3&#x02013;3.7), viral load more than 1000 copies/ml (OR: 2.0; 95% CI: 1.2&#x02013;3.4), and CD4 cells count of less than 200 cells/mm<sup>3</sup> (OR: 3.8; 95% CI: 1.9&#x02013;7.9) were also found to be at increased risk of SIL.</p><table-wrap id="pone-0097150-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0097150.t002</object-id><label>Table 2</label><caption><title>The relationship between sociodemographic and biological variables and cervical smear status.</title></caption><alternatives><graphic id="pone-0097150-t002-2" xlink:href="pone.0097150.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Characteristics</td><td align="left" rowspan="1" colspan="1">Normal smear[n&#x0200a;=&#x0200a;913(%)]</td><td align="left" rowspan="1" colspan="1">SIL [n&#x0200a;=&#x0200a;96(%)]</td><td align="left" rowspan="1" colspan="1">HSIL[n&#x0200a;=&#x0200a;29(%)]</td><td align="left" rowspan="1" colspan="1">SIL[Odd Ratio(95% CI)]</td><td align="left" rowspan="1" colspan="1">HSIL[Odd Ration (95% CI)]</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Age</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Less than 35</td><td align="left" rowspan="1" colspan="1">347(38.1)</td><td align="left" rowspan="1" colspan="1">43 (44.8)</td><td align="left" rowspan="1" colspan="1">14(48.3)</td><td align="left" rowspan="1" colspan="1">1.31(0.8&#x02013;2.1)</td><td align="left" rowspan="1" colspan="1">1.5(0.7&#x02013;3.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;35</td><td align="left" rowspan="1" colspan="1">562(61.9)</td><td align="left" rowspan="1" colspan="1">53(55.2)</td><td align="left" rowspan="1" colspan="1">15(51.7)</td><td align="left" rowspan="1" colspan="1">1(ref)</td><td align="left" rowspan="1" colspan="1">1(ref)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Educational Status</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;Secondary</td><td align="left" rowspan="1" colspan="1">200(21.9)</td><td align="left" rowspan="1" colspan="1">28(28.7)</td><td align="left" rowspan="1" colspan="1">8(27.6)</td><td align="left" rowspan="1" colspan="1">1.4(0.9&#x02013;2.4)</td><td align="left" rowspan="1" colspan="1">1.4(0.5&#x02013;3.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;Secondary</td><td align="left" rowspan="1" colspan="1">713(78.1)</td><td align="left" rowspan="1" colspan="1">68(71.3)</td><td align="left" rowspan="1" colspan="1">21(72.4)</td><td align="left" rowspan="1" colspan="1">1(ref)</td><td align="left" rowspan="1" colspan="1">1(ref)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Marital status</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Unmarried</td><td align="left" rowspan="1" colspan="1">285(31.3)</td><td align="left" rowspan="1" colspan="1">41(42.7)</td><td align="left" rowspan="1" colspan="1">12(41.4)</td><td align="left" rowspan="1" colspan="1">1.6(1.0&#x02013;2.6)</td><td align="left" rowspan="1" colspan="1">1.6(0.7&#x02013;3.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Married</td><td align="left" rowspan="1" colspan="1">625(68.7)</td><td align="left" rowspan="1" colspan="1">55(57.3)</td><td align="left" rowspan="1" colspan="1">17(58.6)</td><td align="left" rowspan="1" colspan="1">1(ref)</td><td align="left" rowspan="1" colspan="1">1(ref)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age at first intercourse</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;20</td><td align="left" rowspan="1" colspan="1">397(2.7)</td><td align="left" rowspan="1" colspan="1">4(4.2)</td><td align="left" rowspan="1" colspan="1">2(6.9)</td><td align="left" rowspan="1" colspan="1">1(ref)</td><td align="left" rowspan="1" colspan="1">1(ref)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;20</td><td align="left" rowspan="1" colspan="1">516(18.5)</td><td align="left" rowspan="1" colspan="1">92(95.8)</td><td align="left" rowspan="1" colspan="1">27(93.1)</td><td align="left" rowspan="1" colspan="1">17.7(6.2&#x02013;57.0)</td><td align="left" rowspan="1" colspan="1">10.4(2.4&#x02013;63.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Life time sexual partners</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">313(35.2)</td><td align="left" rowspan="1" colspan="1">15(15.6)</td><td align="left" rowspan="1" colspan="1">4(13.8)</td><td align="left" rowspan="1" colspan="1">1(ref)</td><td align="left" rowspan="1" colspan="1">1(ref)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;2</td><td align="left" rowspan="1" colspan="1">575(52.7)</td><td align="left" rowspan="1" colspan="1">81(84.4)</td><td align="left" rowspan="1" colspan="1">25(86.2)</td><td align="left" rowspan="1" colspan="1">2.9(1.6&#x02013;5.4)</td><td align="left" rowspan="1" colspan="1">3.4(1.1&#x02013;11.6</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>HIV status</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">551(60.4)</td><td align="left" rowspan="1" colspan="1">20(20.8)</td><td align="left" rowspan="1" colspan="1">5(20.0)</td><td align="left" rowspan="1" colspan="1">1(ref)</td><td align="left" rowspan="1" colspan="1">1(ref)</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">362(39.6)</td><td align="left" rowspan="1" colspan="1">76(79.2)</td><td align="left" rowspan="1" colspan="1">20(80.0)</td><td align="left" rowspan="1" colspan="1">5.8(3.3&#x02013;10.0)</td><td align="left" rowspan="1" colspan="1">6.1(2.1&#x02013;18.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>CD4 cell Count</bold>
<xref ref-type="table-fn" rid="nt102">*</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;200</td><td align="left" rowspan="1" colspan="1">22(6.1)</td><td align="left" rowspan="1" colspan="1">16(16.7)</td><td align="left" rowspan="1" colspan="1">5(20.0)</td><td align="left" rowspan="1" colspan="1">3.8(1.9&#x02013;7.9)</td><td align="left" rowspan="1" colspan="1">4.0(1.2&#x02013;12.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;200</td><td align="left" rowspan="1" colspan="1">413 (93.3)</td><td align="left" rowspan="1" colspan="1">80(83.3)</td><td align="left" rowspan="1" colspan="1">24(80.0)</td><td align="left" rowspan="1" colspan="1">1(ref)</td><td align="left" rowspan="1" colspan="1">1(ref)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>HIV viral load</bold>
<xref ref-type="table-fn" rid="nt102">*</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;1000</td><td align="left" rowspan="1" colspan="1">282(77.9)</td><td align="left" rowspan="1" colspan="1">61(63.5)</td><td align="left" rowspan="1" colspan="1">14(56.0)</td><td align="left" rowspan="1" colspan="1">1(ref)</td><td align="left" rowspan="1" colspan="1">1(ref)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;1000</td><td align="left" rowspan="1" colspan="1">80(22.1)</td><td align="left" rowspan="1" colspan="1">35(36.5)</td><td align="left" rowspan="1" colspan="1">11(44.0)</td><td align="left" rowspan="1" colspan="1">2.0(1.2&#x02013;3.4)</td><td align="left" rowspan="1" colspan="1">2.8(1.1&#x02013;6.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ARV drug use</bold>
<xref ref-type="table-fn" rid="nt102">*</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">74(20.1)</td><td align="left" rowspan="1" colspan="1">32(33.3)</td><td align="left" rowspan="1" colspan="1">10(40.0)</td><td align="left" rowspan="1" colspan="1">2.0(1.3&#x02013;3.7)</td><td align="left" rowspan="1" colspan="1">2.7(1.1&#x02013;6.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">295(79.9)</td><td align="left" rowspan="1" colspan="1">64(66.7)</td><td align="left" rowspan="1" colspan="1">15(60.0)</td><td align="left" rowspan="1" colspan="1">1(ref)</td><td align="left" rowspan="1" colspan="1">1(ref)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>
<bold>*HIV positive women only; SIL: Squamous Intraepithelial lesion; HSIL: High grade Squamous Intraepithelial lesion.</bold>
</p></fn></table-wrap-foot></table-wrap><p>Women living with HIV infection (OR: 6.1; 95% CI: 2.1&#x02013;18.7), were not on antiretroviral drugs (OR: 2.7; 95% CI: 1.1&#x02013;6.6) had a CD4 count less than 200 cells/mm<sup>3</sup> (OR: 4.0; 95% CI: 12.6) and HIV viral load more than 1000 copies/ml (OR: 2.8; 95% CI: 1.1&#x02013;6.8) were found to be at increased risk of HSIL, similar to the pattern observed for SIL. Women who reported more than one life time sexual partner (OR: 3.4; 95% CI: 1.1&#x02013;11.6) or initiated sex at age of 20 years and above (OR: 8.9; 95% CI: 2.0&#x02013;54.3) were also found to be at increased risk of HSIL. However when the effect of the number of life time sexual partnership, was controlled for in a multivariate logistic regression, the association between age at sexual debut above 20 years and both SIL (OR: 9.3; 95% CI: 0.9&#x02013;19.7) and HSIL (OR: 3.9; 95% CI: 0.5&#x02013;27.9) was lost.</p></sec><sec id="s3e"><title>Association between HIV Infection, Immunodeficiency, Antiretroviral Therapy and Cervical Squamous Intraepithelial Lesion</title><p>The association between HIV infection, immunodeficiency, use of antiretroviral therapy and cervical squamous intraepithelial lesion was determined by comparing the distribution of these effect variables among the women with SIL/HSIL and those without SIL/HSIL. The results (crude odd ratios) determined at bivariate analysis (<xref ref-type="table" rid="pone-0097150-t002">table 2</xref>) were further refined at multivariate analysis. In order to assess the effect of different types of exposures on the outcomes, we analyzed and reported our analysis in three models (<xref ref-type="table" rid="pone-0097150-t003">table 3</xref>). The increased risks for SIL (cOR: 5.8; 95% CI: 3.3&#x02013;10.0) and HSIL (cOR: 6.1; 95% CI: 2.1&#x02013;18.71), respectively, observed among HIV positive women relative to HIV negative women in the bivariate analysis were confirmed for both SIL (aOR: 5.4; 95% CI: 2.9&#x02013;8.8) and HSIL (aOR: 5.7; 95% CI: 2.4&#x02013;10.1) after adjustment were made for confounders in the three models.</p><table-wrap id="pone-0097150-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0097150.t003</object-id><label>Table 3</label><caption><title>Relationships between HIV and HIV related variables and squamous intraepithelial lesion (SIL) and high grade squamous intraepithelial lesion (HSIL) after controlling for confounders in a multivariate logistic regression models.</title></caption><alternatives><graphic id="pone-0097150-t003-3" xlink:href="pone.0097150.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Exposure variables and confounders</td><td colspan="2" align="left" rowspan="1">Crude Ratio [OR (95% CI)]</td><td colspan="2" align="left" rowspan="1">Model 1 [OR (95% CI)]</td><td colspan="2" align="left" rowspan="1">Model 2 [OR (95% CI)]</td><td colspan="2" align="left" rowspan="1">Model 3 [OR(95%CI)]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">SIL</td><td align="left" rowspan="1" colspan="1">HSIL</td><td align="left" rowspan="1" colspan="1">SIL</td><td align="left" rowspan="1" colspan="1">HSIL</td><td align="left" rowspan="1" colspan="1">SIL</td><td align="left" rowspan="1" colspan="1">HSIL</td><td align="left" rowspan="1" colspan="1">SIL</td><td align="left" rowspan="1" colspan="1">HSIL</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>HIV Positive status</bold>
</td><td align="left" rowspan="1" colspan="1">5.8(3.3&#x02013;10.0)</td><td align="left" rowspan="1" colspan="1">6.1(2.1&#x02013;18.7)</td><td align="left" rowspan="1" colspan="1">5.6(3.2&#x02013;9.3)</td><td align="left" rowspan="1" colspan="1">6.0 (2.0&#x02013;16.3)</td><td align="left" rowspan="1" colspan="1">5.4(3.2&#x02013;9.1)</td><td align="left" rowspan="1" colspan="1">5.8 (2.6&#x02013;12.3)</td><td align="left" rowspan="1" colspan="1">5.5(3.3&#x02013;9.9)</td><td align="left" rowspan="1" colspan="1">5.6(3.1&#x02013;11.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age<xref ref-type="table-fn" rid="nt103">a</xref> and marital status<xref ref-type="table-fn" rid="nt104">b</xref>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">5.2(3.1&#x02013;9.1)</td><td align="left" rowspan="1" colspan="1">5.6 (2.6&#x02013;11.3)</td><td align="left" rowspan="1" colspan="1">5.1(3.0&#x02013;8.9)</td><td align="left" rowspan="1" colspan="1">5.1 (2.2&#x02013;10.5)</td><td align="left" rowspan="1" colspan="1">5.1(3.4&#x02013;8.1)</td><td align="left" rowspan="1" colspan="1">5.1(2.2&#x02013;10.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age at first intercourse<xref ref-type="table-fn" rid="nt105">c</xref>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">4.7(1.9&#x02013;9.5)</td><td align="left" rowspan="1" colspan="1">5.7 (2.1&#x02013;9.1)</td><td align="left" rowspan="1" colspan="1">4.8(2.1&#x02013;9.3)</td><td align="left" rowspan="1" colspan="1">5.7(2.1&#x02013;9.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Life time sexual partner<xref ref-type="table-fn" rid="nt106">d</xref>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">5.4(2.9&#x02013;8.8)</td><td align="left" rowspan="1" colspan="1">5.7(2.4&#x02013;10.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Use of ARV drugs</bold>
<xref ref-type="table-fn" rid="nt108">*</xref>
</td><td align="left" rowspan="1" colspan="1">2.0(1.3&#x02013;3.7)</td><td align="left" rowspan="1" colspan="1">2.7(1.1&#x02013;6.6)</td><td align="left" rowspan="1" colspan="1">1.9(1.0&#x02013;3.3)</td><td align="left" rowspan="1" colspan="1">2.7(1.2&#x02013;6.8)</td><td align="left" rowspan="1" colspan="1">2.0(1.0&#x02013;3.7)</td><td align="left" rowspan="1" colspan="1">2.5(0.8&#x02013;6.7)</td><td align="left" rowspan="1" colspan="1">2.0(1.2&#x02013;3.5)</td><td align="left" rowspan="1" colspan="1">2.6(1.0&#x02013;6.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age and marital status</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">2.0(1.2&#x02013;3.5)</td><td align="left" rowspan="1" colspan="1">2.6(1.3&#x02013;6.7)</td><td align="left" rowspan="1" colspan="1">2.0(1.3&#x02013;3.6)</td><td align="left" rowspan="1" colspan="1">2.7(0.8&#x02013;6.8)</td><td align="left" rowspan="1" colspan="1">2.0(1.1&#x02013;3.3)</td><td align="left" rowspan="1" colspan="1">2.6(1.0&#x02013;6.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age at first intercourse</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">1.8(1.2&#x02013;3.9)</td><td align="left" rowspan="1" colspan="1">2.7(0.9&#x02013;6.9)</td><td align="left" rowspan="1" colspan="1">2.1(1.4&#x02013;3.4)</td><td align="left" rowspan="1" colspan="1">2.7(1.1&#x02013;6.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Life time sexual partner</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">2.1(1.4&#x02013;3.5)</td><td align="left" rowspan="1" colspan="1">2.6(1.1&#x02013;6.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>CD4 cell count &#x0003c;200 cells/mm<sup>3</sup></bold>
<xref ref-type="table-fn" rid="nt108">*</xref>
</td><td align="left" rowspan="1" colspan="1">3.2(1.5&#x02013;6.6</td><td align="left" rowspan="1" colspan="1">4.0(1.2&#x02013;12.6)</td><td align="left" rowspan="1" colspan="1">3.5(2.1&#x02013;7.5)</td><td align="left" rowspan="1" colspan="1">4.1(3.5&#x02013;11.6)</td><td align="left" rowspan="1" colspan="1">3.7(2.0&#x02013;7.1)</td><td align="left" rowspan="1" colspan="1">4.6(3.2&#x02013;10.1)</td><td align="left" rowspan="1" colspan="1">2.0(1.0&#x02013;6.1)</td><td align="left" rowspan="1" colspan="1">4.9(3.0&#x02013;12.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age at first intercourse</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">3.3(2.0&#x02013;6.5)</td><td align="left" rowspan="1" colspan="1">4.2(2.8&#x02013;10.9)</td><td align="left" rowspan="1" colspan="1">3.1(1.9&#x02013;9.3)</td><td align="left" rowspan="1" colspan="1">4.7(0.9&#x02013;11.1)</td><td align="left" rowspan="1" colspan="1">2.7.1(1.7&#x02013;9.1)</td><td align="left" rowspan="1" colspan="1">5.1(3.4&#x02013;10.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Life time sexual partner</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">3.0(0.9&#x02013;10.1)</td><td align="left" rowspan="1" colspan="1">4.2(0.9&#x02013;9.4)</td><td align="left" rowspan="1" colspan="1">2.8.1(0.9&#x02013;9.2)</td><td align="left" rowspan="1" colspan="1">5.0(3.1&#x02013;11.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Antiretroviral drug use<xref ref-type="table-fn" rid="nt107">e</xref>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="left" rowspan="1" colspan="1">1.9(1.1&#x02013;5.9)</td><td align="left" rowspan="1" colspan="1">5.7(1.1&#x02013;7.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>HIV viral load above 1000 copies/ml</bold>
<xref ref-type="table-fn" rid="nt108">*</xref>
</td><td align="left" rowspan="1" colspan="1">2.0(1.2&#x02013;3.4)</td><td align="left" rowspan="1" colspan="1">2.8(1.1&#x02013;6.8)</td><td align="left" rowspan="1" colspan="1">2.0(1.0&#x02013;3.2)</td><td align="left" rowspan="1" colspan="1">2.8(1.1&#x02013;6.6)</td><td align="left" rowspan="1" colspan="1">1.8(1.1&#x02013;3.1)</td><td align="left" rowspan="1" colspan="1">2.8(1.2&#x02013;6.9)</td><td align="left" rowspan="1" colspan="1">1.9(1.1&#x02013;3.6)</td><td align="left" rowspan="1" colspan="1">2.8(1.1&#x02013;4.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age at first intercourse</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.9(1.1&#x02013;3.1)</td><td align="left" rowspan="1" colspan="1">2.8(1.1&#x02013;6.8)</td><td align="left" rowspan="1" colspan="1">1.9(1.0&#x02013;3.4)</td><td align="left" rowspan="1" colspan="1">2.7(1.0&#x02013;6.6)</td><td align="left" rowspan="1" colspan="1">1.8(0.9&#x02013;3.4)</td><td align="left" rowspan="1" colspan="1">2.6(1.0&#x02013;4.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Life time sexual partner</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.9(1.0&#x02013;3.5)</td><td align="left" rowspan="1" colspan="1">2.7(1.2&#x02013;6.4)</td><td align="left" rowspan="1" colspan="1">1.9(1.1&#x02013;3.6)</td><td align="left" rowspan="1" colspan="1">2.7(1.0&#x02013;5.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Antiretroviral drug use</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.9(0.8&#x02013;3.7)</td><td align="left" rowspan="1" colspan="1">2.7(0.7&#x02013;5.7)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label>a</label><p>Age groups: 18&#x02013;35 and &#x02265;35 (ref) years;</p></fn><fn id="nt104"><label>b</label><p>Marital status: Married and unmarried (ref);</p></fn><fn id="nt105"><label>c</label><p>Age at first intercourse: &#x0003c;20 (ref) and &#x02265;20 years;</p></fn><fn id="nt106"><label>d</label><p>Life time sexual partner: 1 (ref) and &#x02265;2;</p></fn><fn id="nt107"><label>e</label><p>Antiretroviral drug use: Yes(ref) and No.</p></fn><fn id="nt108"><label/><p>
<bold>*HIV positive women only.</bold>
</p></fn></table-wrap-foot></table-wrap><p>HIV positive women with CD4 cell count &#x0003c;200 cells/mm<sup>3</sup> were also found to be at increased risk for SIL (aOR: 1.9; 95% CI: 1.1&#x02013;5.9) and HSIL (aOR: 5.7; 95% CI: 1.1&#x02013;7.2) respectively, compared to women with CD4 cell count above 200 cells/mm<sup>3</sup> after adjustment for confounders in the three models. HIV positive women who were not on ARV treatment were found to be at increased risk for both SIL (aOR: 2.1; 95% CI: 1.4&#x02013;3.5) and HSIL (aOR: 2.6; 95% CI: 1.1&#x02013;6.4), compared to women on HAART. HIV viral load above 1000 copies did not retain its independent association with SIL (aOR: 1.9; 95% CI: 0.8&#x02013;3.7) or HSIL (aOR: 2.7; 95% CI: 0.7&#x02013;5.7) after adjustment was made for the use of antiretroviral drugs in the final model (<xref ref-type="table" rid="pone-0097150-t003">table 3</xref>).</p></sec></sec><sec id="s4"><title>Discussion</title><p>The prevalence of cervical squamous intraepithelial lesion (SIL) in this study was 8.4%, with a higher prevalence of 14.3% in HIV positive women compared to 3.3% in HIV negative women (aOR: 5.4; 95% CI: 2.9&#x02013;8.8). HIV positive women not on antiretroviral drugs were found to be at a higher risk for both SIL (aOR: 2.1; 95% CI: 1.4&#x02013;3.5) and HSIL (aOR: 2.6; 95% CI: 1.1&#x02013;6.4) compared to those on antiretroviral drugs. Severely immune-compromised women (CD4 &#x0003c;200 cells/mm<sup>3</sup>) were also found to be at a higher risk for the development of both SIL (aOR: 1.9; 95% CI: 1.1&#x02013;5.9) and HSIL (aOR: 5.7; 95% CI: 1.1&#x02013;7.2) compared to those with CD4 cell count above 200 cells/mm<sup>3</sup>. No association was found between HIV viral load and SIL (aOR: 1.9;95% CI: 0.8&#x02013;3.7).</p><p>Anorlu et al <xref rid="pone.0097150-Anorlu1" ref-type="bibr">[23]</xref>, Durowede et al <xref rid="pone.0097150-Durowade1" ref-type="bibr">[24]</xref> and Pimentel et al <xref rid="pone.0097150-Pimentel1" ref-type="bibr">[25]</xref> in their separate studies reported lower SIL prevalence of 5.0%, 5.0% and 6.8%, respectively, in Lagos, Okene and Olufadi in Nigeria. The difference between the findings of these studies and our study may be due to the large proportion of HIV positive persons in our cohort. In the presence of HIV infection and the associated immune-depression, the body is unable to eliminate HPV leading to the persistence of oncogenic HPV genotypes, which ultimately results in the development of precancerous lesions and invasive carcinoma <xref rid="pone.0097150-Strickler1" ref-type="bibr">[27]</xref>. The finding of significantly higher rate of SIL among the HIV positive women (14.3%) compared to the HIV negative (3.3%) in this study further supports the previously reported association between HIV, HPV and cervical precancerous lesions <xref rid="pone.0097150-Blitz1" ref-type="bibr">[15]</xref>, <xref rid="pone.0097150-Chen1" ref-type="bibr">[16]</xref>, <xref rid="pone.0097150-Ezechi1" ref-type="bibr">[28]</xref>&#x02013;<xref rid="pone.0097150-Odida2" ref-type="bibr">[30]</xref>. The prevalence of SIL among HIV positive women in this study is within the range of 10.9&#x02013;17.8% reported among HIV positive women by Anorlu et al <xref rid="pone.0097150-Anorlu2" ref-type="bibr">[31]</xref>, Sewande et al <xref rid="pone.0097150-Swende1" ref-type="bibr">[22]</xref> and Chalermchockcharoenkit et al <xref rid="pone.0097150-Chalermchockcharoenkit1" ref-type="bibr">[32]</xref> in Nigeria and Thailand but lower than rates reported among the HIV-positive women in Jos, Nigeria (29%) <xref rid="pone.0097150-Agaba1" ref-type="bibr">[19]</xref> and Helsinki Finland (33%) <xref rid="pone.0097150-Lehtovirta1" ref-type="bibr">[33]</xref>.</p><p>The risk of developing SIL and HSIL was found to be higher in HIV positive women with severe immunosuppression, which is in support of previous studies from southern Africa, North America and Asia that reported higher prevalence of SIL among severely immune-compromised women <xref rid="pone.0097150-Zeier1" ref-type="bibr">[13]</xref>&#x02013;<xref rid="pone.0097150-Chen1" ref-type="bibr">[16]</xref>. The independent association between SIL and severe immunosuppression was retained after controlling for the use of antiretroviral drugs, confirming the independent effect of severe immunosuppression with poor clearance of HPV from cervical cells and eventual transformation of SIL to invasive cancer <xref rid="pone.0097150-Xi1" ref-type="bibr">[14]</xref>, <xref rid="pone.0097150-McKenzie1" ref-type="bibr">[17]</xref>, <xref rid="pone.0097150-Mogtomo1" ref-type="bibr">[18]</xref>, Agaba et al <xref rid="pone.0097150-Agaba1" ref-type="bibr">[19]</xref> and Sewande et al <xref rid="pone.0097150-Swende1" ref-type="bibr">[22]</xref> reported that the immunosuppressive effect, measured by the decrease in CD4 cell count, is the greatest predictor of cervical lesion development in HIV-positive women. Unlike the observed association between low CD4 count and SIL, the association between high HIV viral load and risk of SIL was not retained after adjustment was made for use of antiretroviral drugs. This suggests that HIV viral load as a factor does not influence the development of SIL, rather the initially observed association may be due to high viral load among participants not on HAART. Confirming further the protective effect of antiretroviral drugs against the development of SIL <xref rid="pone.0097150-Xi1" ref-type="bibr">[14]</xref>, <xref rid="pone.0097150-McKenzie1" ref-type="bibr">[17]</xref>, <xref rid="pone.0097150-Mogtomo1" ref-type="bibr">[18]</xref>, data from this study showed an increased risk of both SIL (aOR: 2.1; 95% CI: 1.4&#x02013;3.5) and HSIL (aOR: 2.6; 95% CI: 1.1&#x02013;6.4) among participants not on HAART. Similar observation was reported by Firnhaber and colleagues in South Africa <xref rid="pone.0097150-Firnhaber1" ref-type="bibr">[12]</xref>. Antiretroviral drugs, by controlling HIV replication and reversing the weakening of the immune response and system, reduces the risks of development of cervical lesion and their progression to invasive cancer by enhancing the cervical cells ability to eliminate HPV infection and prevent persistence <xref rid="pone.0097150-Strickler1" ref-type="bibr">[27]</xref>.</p><p>Our study is the first in Nigeria and the West African sub region to show a beneficial effect of antiretroviral drug use in reducing the risk of cervical squamous intraepithelial lesion. This finding could be important, in that the West African sub region has a specific mix of HIV types and strains and findings from elsewhere may not easily be extrapolated. Secondly studies have shown that HIV type and strains influence disease progression, interactions and outcome <xref rid="pone.0097150-National1" ref-type="bibr">[34]</xref>.</p><p>In low income countries, including Nigeria, where integration of cervical cancer screening into HIV care has been a major challenge <xref rid="pone.0097150-Ezechi2" ref-type="bibr">[35]</xref>, the possible protective effect of antiretroviral drugs against SIL found in this study could be used as advocacy tool for service integration. This finding could also add impetus to the current global public health strategy of test and treat in HIV care as a means of prevention of HIV transmission. Its implementation will in addition to reducing new HIV infection, also reduce cervical cancer incidence among HIV positive women.</p><p>Though our study has contributed new information to the body of knowledge on the relationship between HIV infection, immunosuppression, antiretroviral drug use and cervical squamous intraepithelial lesion, it needs to be interpreted with caution as it was a cross-sectional study conducted in one of the six regions of Nigeria. However, the cosmopolitan nature of the south western region, the sociocultural and ethnic diversity similar to what is obtained nationally might infer a fair representation of the situation in the whole country. The obtained information might therefore be reasonably generalizable. The long recruitment period for this study may have addressed the lack of diversity and variation associated with cross-sectional studies. The recruitment of most of HIV positive women from NIMR and the majority of HIV negative women from the community may have introduced some selection bias, however over 65% of these HIV positive women come from the same community as the HIV negatives. In addition, this strategy was considered feasible to enrol an adequate number of HIV positive participants due to the low HIV prevalence in Lagos and Ogun states.</p><p>The study has various strengths, of which diversity in the type of women recruited in the study is an important one. The inclusion of women of diverse characteristics including HIV positive and negative women, rural as well as urban women, treatment na&#x000ef;ve and experienced women, severely immune-compromised and immunocompetent HIV positive women, could make the generalisation of the findings easier. The large number of HIV positive women in this study made it possible to conclusively demonstrate the effect of the stage of HIV infection and treatment on the prevalence and burden of SIL.</p><p>The use of midwives in the implementation of the study related activities was found to be a useful strategy. We noted that with support, supervision and institution of quality assurance system, tasks originally belonging to the medical profession may successfully be shifted to another cadre in order to meet the demand-response in resource poor public health settings <xref rid="pone.0097150-Ezechi2" ref-type="bibr">[35]</xref>, <xref rid="pone.0097150-WHO1" ref-type="bibr">[36]</xref>. Improving access to antiretroviral drugs among HIV positive women as cervical cancer prevention in remote regions of our sub region requires shifting this task to the nurses and midwives in the primary and secondary health facilities.</p></sec><sec id="s5"><title>Conclusion</title><p>HIV infection and severe immunosuppression were found to be associated with increased risk of cervical squamous intraepithelial lesion but high viral load was not. For the first time, in West African sub-region with specific HIV type and strains, we established that antiretroviral drug use protects against the development of SIL.</p><p>Integration of cervical cancer screening programme into HIV services and early initiation of antiretroviral drug in HIV positive women especially those with severe immune-suppression could therefore prove to be useful in preventing and controlling cervical cancer development in HIV positive women.</p></sec></body><back><ack><p>We sincerely thank Drs. Titi Gbajabiamila, Chidinma Gab &#x02013; Okafor, Ms. Ifeoma Idigbe, Tumike Kuyoro and Mrs Eva Amadi for their assistance with data and sample collection and Oba Rasheed for coordinating data entry. We are also grateful to the staff of Clinical Sciences Division, HIV testing and counselling centre and Human virology laboratory, Nigerian Institute of Medical Research, Lagos.</p></ack><ref-list><title>References</title><ref id="pone.0097150-Musa1"><label>1</label><mixed-citation publication-type="other">Musa Z, Odunukwe NN, Onwujekwe DI, Ezechi OC, Kalejaiye OO, <etal>et al</etal> (2010) Characteristics at baseline of adult HIV/AIDS patients over the years: 5 years case review. 5<sup>th</sup> National Conference on HIV/AIDS, Abuja. 2&#x02013;5<sup>th</sup> May 2010. Abstract number TuOrC02; 04.</mixed-citation></ref><ref id="pone.0097150-Shah1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Shah</surname><given-names>RM</given-names></name>, <name><surname>Bulgiba</surname><given-names>A</given-names></name>, <name><surname>Lee</surname><given-names>CKC</given-names></name>, <name><surname>Haniff</surname><given-names>J</given-names></name>, <name><surname>Ali</surname><given-names>MM</given-names></name> (<year>2012</year>) <article-title>Highly active antiretoviral therapy reduces mortality and morbidity in patients with AIDS in Songai Balot Hospital Journal of Experimental and Clinical Medicine</article-title>. <volume>4(4)</volume>: <fpage>239</fpage>&#x02013;<lpage>244</lpage>.</mixed-citation></ref><ref id="pone.0097150-Jevtovi1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Jevtovi&#x00107;</surname><given-names>D</given-names></name>, <name><surname>Dragovi&#x00107;s</surname><given-names>G</given-names></name>, <name><surname>Salemovi&#x00107;</surname><given-names>D</given-names></name>, <name><surname>Ranin</surname><given-names>J</given-names></name>, <name><surname>Ku&#x00161;i&#x00107;</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Treatment outcome of HAART-treated patients in a resource-limited setting: The Belgrade Cohort Study</article-title>. <source>Biomed Pharmacother</source>
<comment>S0753-3322(14)00004-3. doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.biopha.2014.01.001">10.1016/j.biopha.2014.01.001</ext-link></comment>
</mixed-citation></ref><ref id="pone.0097150-Bernstein1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Bernstein</surname><given-names>WB</given-names></name>, <name><surname>Little</surname><given-names>RF</given-names></name>, <name><surname>Wilson</surname><given-names>WH</given-names></name>, <name><surname>Yarchoan</surname><given-names>R</given-names></name> (<year>2006</year>) <article-title>Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy</article-title>. <source>Int J Hematol</source>
<volume>84(1)</volume>: <fpage>3</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">16867895</pub-id></mixed-citation></ref><ref id="pone.0097150-Adler1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Adler</surname><given-names>DH</given-names></name> (<year>2010</year>) <article-title>The impact of HAART on HPV-related cervical disease</article-title>. <source>Curr HIV Res</source>
<volume>8(7)</volume>: <fpage>493</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">20946095</pub-id></mixed-citation></ref><ref id="pone.0097150-Gates1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Gates</surname><given-names>AE</given-names></name>, <name><surname>Kaplan</surname><given-names>LD</given-names></name> (<year>2002</year>) <article-title>AIDS malignancies in the era of highly active antiretroviral therapy</article-title>. <source>Oncology (Williston Park)</source>
<volume>16(5)</volume>: <fpage>657</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">12108891</pub-id></mixed-citation></ref><ref id="pone.0097150-Odida1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Odida</surname><given-names>M</given-names></name>, <name><surname>Sandin</surname><given-names>S</given-names></name>, <name><surname>Mirembe</surname><given-names>F</given-names></name>, <name><surname>Kleter</surname><given-names>B</given-names></name>, <name><surname>Quint</surname><given-names>W</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>HPV types, HIV and invasive cervical carcinoma risk in Kampala, Uganda: a case-control study</article-title>. <source>Infectious Agents and Cancer</source>
<volume>6</volume>: <fpage>8</fpage> Available: <ext-link ext-link-type="uri" xlink:href="http://www.infectagentscancer.com/content/6/1/8">http://www.infectagentscancer.com/content/6/1/8</ext-link>.<pub-id pub-id-type="pmid">21702999</pub-id></mixed-citation></ref><ref id="pone.0097150-terMeulen1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>ter Meulen</surname><given-names>J</given-names></name>, <name><surname>Eberhardt</surname><given-names>HC</given-names></name>, <name><surname>Luande</surname><given-names>J</given-names></name>, <name><surname>Mgaya</surname><given-names>HN</given-names></name>, <name><surname>Chang-Claude</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>1992</year>) <article-title>Human papillomavirus (HPV) infection, HIV infection and cervical cancer in Tanzania, east Africa</article-title>. <source>Int J Cancer</source>
<volume>51</volume>: <fpage>515</fpage>&#x02013;<lpage>521</lpage>.<pub-id pub-id-type="pmid">1318265</pub-id></mixed-citation></ref><ref id="pone.0097150-Schmauz1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Schmauz</surname><given-names>R</given-names></name>, <name><surname>Okong</surname><given-names>P</given-names></name>, <name><surname>de Villiers</surname><given-names>EM</given-names></name>, <name><surname>Dennin</surname><given-names>R</given-names></name>, <name><surname>Brade</surname><given-names>L</given-names></name> (<year>1989</year>) <article-title>Multiple infections in cases of cervical cancer from a high-incidence area in tropical Africa</article-title>. <source>Int J Cancer</source>
<volume>43</volume>: <fpage>805</fpage>&#x02013;<lpage>809</lpage>.<pub-id pub-id-type="pmid">2714885</pub-id></mixed-citation></ref><ref id="pone.0097150-Sekirime1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Sekirime</surname><given-names>WK</given-names></name>, <name><surname>Gray</surname><given-names>R</given-names></name> (<year>2007</year>) <article-title>HIV infection among Uganda women with cervical cancer: a retrospective study</article-title>. <source>Gynecol Obstet Invest</source>
<volume>63</volume>: <fpage>222</fpage>&#x02013;<lpage>228</lpage>.<pub-id pub-id-type="pmid">17191009</pub-id></mixed-citation></ref><ref id="pone.0097150-Kahesa1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Kahesa</surname><given-names>C</given-names></name>, <name><surname>Mwaiselage</surname><given-names>J</given-names></name>, <name><surname>Wabinga</surname><given-names>HR</given-names></name>, <name><surname>Ngoma</surname><given-names>T</given-names></name>, <name><surname>Kalyango</surname><given-names>JN</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Association between invasive cancer of the cervix and HIV-1 infection in Tanzania: the need for dual screening</article-title>. <source>BMC Public Health</source>
<volume>8</volume>: <fpage>262</fpage>.<pub-id pub-id-type="pmid">18664298</pub-id></mixed-citation></ref><ref id="pone.0097150-Firnhaber1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Firnhaber</surname><given-names>C</given-names></name>, <name><surname>Westreich</surname><given-names>D</given-names></name>, <name><surname>Schulze</surname><given-names>D</given-names></name>, <name><surname>Williams</surname><given-names>S</given-names></name>, <name><surname>Siminya</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Highly active antiretroviral therapy and cervical dysplasia in HIV-positive women in South Africa</article-title>. <source>J Int AIDS Soc</source>
<volume>15(2)</volume>: <fpage>17382</fpage>.<pub-id pub-id-type="pmid">22713259</pub-id></mixed-citation></ref><ref id="pone.0097150-Zeier1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Zeier</surname><given-names>MD</given-names></name>, <name><surname>Botha</surname><given-names>MH</given-names></name>, <name><surname>van der</surname><given-names>M</given-names></name>, <name><surname>Frederick</surname><given-names>H</given-names></name>, <name><surname>Eshun-Wilson</surname><given-names>I</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Progression and Persistence of Low-Grade Cervical Squamous Intraepithelial Lesions in Women Living With Human Immunodeficiency Virus</article-title>. <source>Journal of Lower Genital Tract Disease</source>
<volume>16(3)</volume>: <fpage>243</fpage>&#x02013;<lpage>250</lpage>.<pub-id pub-id-type="pmid">22460273</pub-id></mixed-citation></ref><ref id="pone.0097150-Xi1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Xi</surname><given-names>LF</given-names></name>, <name><surname>Kivat</surname><given-names>NB</given-names></name> (<year>2005</year>) <article-title>Cervical neoplasia and highly active antiretroviral therapy</article-title>. <source>Journal of the National Cancer Institute 96</source>
<volume>(14)</volume>: <fpage>1051</fpage>&#x02013;<lpage>1054</lpage>.</mixed-citation></ref><ref id="pone.0097150-Blitz1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Blitz</surname><given-names>S</given-names></name>, <name><surname>Baxter</surname><given-names>J</given-names></name>, <name><surname>Raboud</surname><given-names>J</given-names></name>, <name><surname>Walmsley</surname><given-names>S</given-names></name>, <name><surname>Rachlis</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. J Infect Dis</article-title>. <volume>20138(3)</volume>: <fpage>454</fpage>&#x02013;<lpage>62</lpage>.</mixed-citation></ref><ref id="pone.0097150-Chen1"><label>16</label><mixed-citation publication-type="other">Chen YC, Li CY, Liu HY, Lee NY, Ko WC, <etal>et al</etal> (2013) Effect of antiretroviral therapy on the incidence of cervical neoplasia among HIV-infected women: a population-based cohort study in Taiwan. AID Dec 10. [Epub ahead of print]. Available: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24326354">http://www.ncbi.nlm.nih.gov/pubmed/24326354</ext-link>.</mixed-citation></ref><ref id="pone.0097150-McKenzie1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>McKenzie</surname><given-names>KP</given-names></name>, <name><surname>Rogers</surname><given-names>RK</given-names></name>, <name><surname>Njoroge</surname><given-names>JW</given-names></name>, <name><surname>John-Stewart</surname><given-names>G</given-names></name>, <name><surname>Richardson</surname><given-names>BA</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Cervical squamous intraepithelial lesions among HIV-positive women on antiretroviral therapy in Kenya</article-title>. <source>Curr HIV Res</source>
<volume>9(3)</volume>: <fpage>180</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">21585334</pub-id></mixed-citation></ref><ref id="pone.0097150-Mogtomo1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Mogtomo</surname><given-names>ML</given-names></name>, <name><surname>Malieugoue</surname><given-names>LC</given-names></name>, <name><surname>Djiepgang</surname><given-names>C</given-names></name>, <name><surname>Wankam</surname><given-names>M</given-names></name>, <name><surname>Moune</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Incidence of cervical disease associated to HPV in human immunodeficiency infected women under highly active antiretroviral therapy. Infect Agent Cancer</article-title>. <source>3</source>
<volume>4</volume>: <fpage>9</fpage>
<comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1750-9378-4-9">10.1186/1750-9378-4-9</ext-link></comment>
</mixed-citation></ref><ref id="pone.0097150-Agaba1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Agaba</surname><given-names>PA</given-names></name>, <name><surname>Thacher</surname><given-names>TD</given-names></name>, <name><surname>Ekwempu</surname><given-names>CC</given-names></name>, <name><surname>Idoko</surname><given-names>JA</given-names></name> (<year>2009</year>) <article-title>Cervical dysplasia in Nigerian women Infected with HIV</article-title>. <source>International Journal of Gynecology and Obstetrics</source>
<volume>107</volume>: <fpage>99</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">19619874</pub-id></mixed-citation></ref><ref id="pone.0097150-Chama1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Chama</surname><given-names>CM</given-names></name>, <name><surname>Nggada</surname><given-names>H</given-names></name>, <name><surname>Gaushau</surname><given-names>W</given-names></name> (<year>2005</year>) <article-title>Cervical dysplasia in HIV infected women in Maiduguri, Nigerian Journal of Obstetrics and Gynaecology</article-title>. <volume>25(3)</volume>: <fpage>286</fpage>&#x02013;<lpage>288</lpage>.</mixed-citation></ref><ref id="pone.0097150-Akinwuntan1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Akinwuntan</surname><given-names>AL</given-names></name>, <name><surname>Adesina</surname><given-names>OA</given-names></name>, <name><surname>Okolo</surname><given-names>CA</given-names></name>, <name><surname>Oluwasola</surname><given-names>OA</given-names></name>, <name><surname>Oladokun</surname><given-names>O</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Correlation of cervical cytology and visual inspection with acetic acid in HIV-positive women</article-title>. <source>Journal of Obstetrics and Gynaecology</source>
<volume>28(6)</volume>: <fpage>638</fpage>&#x02013;<lpage>641</lpage>.<pub-id pub-id-type="pmid">19003664</pub-id></mixed-citation></ref><ref id="pone.0097150-Swende1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Swende</surname><given-names>TZ</given-names></name>, <name><surname>Ngwan</surname><given-names>SD</given-names></name>, <name><surname>Swende</surname><given-names>LT</given-names></name> (<year>2012</year>) <article-title>Prevalence and risk factors for cervical squamous intraepithelial lesions among women infected with HIV-1 in Makurdi, Nigeria</article-title>. <source>International Journal of Women&#x02019;s Health</source>
<volume>4</volume>: <fpage>55</fpage>&#x02013;<lpage>60</lpage>.</mixed-citation></ref><ref id="pone.0097150-Anorlu1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Anorlu</surname><given-names>RI</given-names></name>, <name><surname>Abdul-Kareem</surname><given-names>FB</given-names></name>, <name><surname>Abudu</surname><given-names>OO</given-names></name>, <name><surname>Oyekan</surname><given-names>TO</given-names></name> (<year>2003</year>) <article-title>Cervical cytology in an urban population in Lagos, Nigeria</article-title>. <source>J Obstet Gynaecol</source>
<volume>23(3)</volume>: <fpage>285</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">12850863</pub-id></mixed-citation></ref><ref id="pone.0097150-Durowade1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Durowade</surname><given-names>KA</given-names></name>, <name><surname>Osagbemi</surname><given-names>GK</given-names></name>, <name><surname>Salaudeen</surname><given-names>AG</given-names></name>, <name><surname>Musa</surname><given-names>OI</given-names></name>, <name><surname>Akande</surname><given-names>TM</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Prevalence and risk factors of cervical cancer among women in an urban community of Kwara State, north central Nigeria</article-title>. <source>J Prev Med Hyg</source>
<volume>53(4)</volume>: <fpage>213</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">23469591</pub-id></mixed-citation></ref><ref id="pone.0097150-Pimentel1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Pimentel</surname><given-names>VM</given-names></name>, <name><surname>Jiang</surname><given-names>X</given-names></name>, <name><surname>Mandavilli</surname><given-names>S</given-names></name>, <name><surname>Umenyi N</surname><given-names>C</given-names></name>, <name><surname>Schnatz</surname><given-names>PF</given-names></name> (<year>2013</year>) <article-title>Prevalence of high-risk cervical human papillomavirus and squamous intraepithelial lesion in Nigeria. J Low Genit Tract Dis</article-title>. <volume>17(2)</volume>: <fpage>203</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="pone.0097150-Davey1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Davey</surname><given-names>DD</given-names></name> (<year>2003</year>) <article-title>Cervical cytology classification and Bethesda system</article-title>. <source>The Cancer Journal</source>
<volume>9(5)</volume>: <fpage>327</fpage>&#x02013;<lpage>334</lpage>.<pub-id pub-id-type="pmid">14690307</pub-id></mixed-citation></ref><ref id="pone.0097150-Strickler1"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Strickler</surname><given-names>HD</given-names></name>, <name><surname>Burk</surname><given-names>RD</given-names></name>, <name><surname>Fazzari</surname><given-names>M</given-names></name>, <name><surname>Anastos</surname><given-names>K</given-names></name>, <name><surname>Minkoff</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women</article-title>. <source>J Natl Cancer Inst</source>
<volume>97</volume>: <fpage>577</fpage>&#x02013;<lpage>586</lpage>.<pub-id pub-id-type="pmid">15840880</pub-id></mixed-citation></ref><ref id="pone.0097150-Ezechi1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Ezechi</surname><given-names>OC</given-names></name>, <name><surname>Ostergren</surname><given-names>PO</given-names></name>, <name><surname>Nwaokorie</surname><given-names>FO</given-names></name>, <name><surname>Ujah</surname><given-names>IA</given-names></name>, <name><surname>Odberg Pettersson</surname><given-names>K</given-names></name> (<year>2014</year>) <article-title>The burden, distribution and risk factors for cervical oncogenic human papilloma virus infection in HIV positive Nigerian women</article-title>. <source>Virology Journal</source>
<volume>11</volume>: <fpage>5</fpage>
<comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1743-422X-11-5">10.1186/1743-422X-11-5</ext-link></comment>
<pub-id pub-id-type="pmid">24433568</pub-id></mixed-citation></ref><ref id="pone.0097150-Banura1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Banura</surname><given-names>C</given-names></name>, <name><surname>Franceschi</surname><given-names>S</given-names></name>, <name><surname>van Doorn</surname><given-names>L</given-names></name>, <name><surname>Arslan</surname><given-names>A</given-names></name>, <name><surname>Wabwire-Mangen</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Infection with Human Papillomavirus and HIV among Young Women in Kampala, Uganda</article-title>. <source>The Journal of Infectious Diseases</source>
<volume>194(4)</volume>: <fpage>555</fpage>&#x02013;<lpage>562</lpage>.</mixed-citation></ref><ref id="pone.0097150-Odida2"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Odida</surname><given-names>M</given-names></name>, <name><surname>de Sanjos&#x000e9;</surname><given-names>S</given-names></name>, <name><surname>Quint</surname><given-names>W</given-names></name>, <name><surname>Bosch</surname><given-names>XF</given-names></name>, <name><surname>Klaustermeier</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Human Papillomavirus type distribution in invasive cervical cancer in Uganda</article-title>. <source>BMC Infectious Diseases</source>
<volume>8</volume>: <fpage>85</fpage>
<comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2334-8-85">10.1186/1471-2334-8-85</ext-link></comment>
<pub-id pub-id-type="pmid">18577214</pub-id></mixed-citation></ref><ref id="pone.0097150-Anorlu2"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Anorlu</surname><given-names>RI</given-names></name>, <name><surname>Igwilo</surname><given-names>CI</given-names></name>, <name><surname>Akanmu</surname><given-names>AS</given-names></name>, <name><surname>Banjo</surname><given-names>AA</given-names></name>, <name><surname>Odunukwe</surname><given-names>NN</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Prevalence of abnormal cervical smears among patients with HIV in Lagos, Nigeria. West Afr J Med</article-title>. <volume>26(2)</volume>: <fpage>143</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="pone.0097150-Chalermchockcharoenkit1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Chalermchockcharoenkit</surname><given-names>A</given-names></name>, <name><surname>Srimai</surname><given-names>K</given-names></name>, <name><surname>Chaisilwattana</surname><given-names>P</given-names></name> (<year>2006</year>) <article-title>High prevalence of cervical squamous cell abnormalities among HIV-infected women with immunological AIDS-defining illnesses</article-title>. <source>J Obstet Gynaecol Res</source>
<volume>32</volume>: <fpage>324</fpage>&#x02013;<lpage>329</lpage>.<pub-id pub-id-type="pmid">16764624</pub-id></mixed-citation></ref><ref id="pone.0097150-Lehtovirta1"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Lehtovirta</surname><given-names>P</given-names></name>, <name><surname>Paavonen</surname><given-names>J</given-names></name>, <name><surname>Heikinheimo</surname><given-names>O</given-names></name> (<year>2008</year>) <article-title>Risk factors, diagnosis and prognosis of cervical intraepithelial neoplasia among HIV-infected women</article-title>. <source>Int J STD AIDS</source>
<volume>19</volume>: <fpage>37</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">18275645</pub-id></mixed-citation></ref><ref id="pone.0097150-National1"><label>34</label><mixed-citation publication-type="other">National Agency for the control of AIDS (2011). Antiretroviral therapy in Nigeria. Available: <ext-link ext-link-type="uri" xlink:href="http://www.naca.gov.ng/content/view/417/language,en/">http://www.naca.gov.ng/content/view/417/language,en/</ext-link>.</mixed-citation></ref><ref id="pone.0097150-Ezechi2"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Ezechi</surname><given-names>OC</given-names></name>, <name><surname>Gab-Okafor</surname><given-names>CV</given-names></name>, <name><surname>Ostergren</surname><given-names>PO</given-names></name>, <name><surname>Odberg Pettersson</surname><given-names>K</given-names></name> (<year>2013</year>) <article-title>Willingness and acceptability of cervical cancer screening among HIV positive Nigerian women</article-title>. <source>BMC Public Health 2013</source>
<volume>13</volume>: <fpage>46</fpage>
<comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2458-13-46">10.1186/1471-2458-13-46</ext-link></comment>
</mixed-citation></ref><ref id="pone.0097150-WHO1"><label>36</label><mixed-citation publication-type="other">WHO (2008). Task shifting: rational redistribution of tasks among health workforce teams: global recommendations and guidelines. WHO Geneva.</mixed-citation></ref></ref-list></back></article>